Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05361395 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Name: First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) — clinical trial record (NCT05361395)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 1

SponsorAmgen

Started2022-08-24

View on ClinicalTrials.gov ↗

This is a phase 1b study to assess the safety and tolerability of tarlatamab in combination with programmed death ligand (PD-L1) inhibition with and without chemotherapy.

Amendment history 2 changes detected by DataLookout

2026-09-10

Primary completion pushed: 2028-08-28 → 2030-05-30

2026-09-10

Completion pushed: 2028-08-28 → 2030-05-30

Trial Details

NCT Number	NCT05361395
Lead Sponsor	Amgen
Conditions	Extensive Stage Small Cell Lung Cancer
Enrollment	184 participants
Start Date	2022-08-24
Primary Completion	2030-05-30 (estimated)
Study Completion	2030-05-30 (estimated)
Updated on ClinicalTrials.gov	2026-09-09